- Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019
- New funds will be used to accelerate the development, manufacturing and commercialisation of in vitro diagnostics for infectious diseases
Mobidiag Ltd. today announces that it has received the second tranche of €10M from the €25M growth capital loan signed with the European Investment Bank Group (EIB) in May 2019. These new funds will be used to advance Mobidiag’s research and development and facilitate further validation and commercialisation of new molecular diagnostics tests using the Company’s Amplidiag® and Novodiag® platforms.
The loan is supported by the European Fund for Strategic Investments (EFSI), the main pillar of Investment Plan for Europe, through the European Growth Finance Facility (EGFF) initiative. This is the second operation between Mobidiag and EIB, following the first loan in 2016 for €15M.